Slide 1: Q3'23 Earnings Presentation
Enabling discovery, safety and production of tomorrow’s therapeutics NASDAQ: HBIO Q3’23 Earnings Presentation Jim Green, Chairman, President & CEO Jennifer Cote, CFO & Treasurer November 07, 2023
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Forward-Looking Statements This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified b
Slide 3: CEO Summary: Q3'23 Highlights
CEO Summary: Q3’23 Highlights Strong growth in Americas impacted by post-Covid-19 headwinds from Asia Pacific $ Million except Income Statement Components Q3' 2023 Q3' 2022 per share data Revenue (GAAP) 25.4 26.9 Growth Rate -5.8% Favorable FX Impact 0.7 Net Reduction in Discontinued Products vs Q3’
Slide 4: Q3'23 Revenue by Geography: Challenges in APAC
Q3’23 Revenue by Geography: Challenges in APAC As Reported FX Adjusted (in $M) Q3 '23 Q3 '22 CMT $ 11.3 $ 14.1 (19.9%) Pre-Clinical 13.4 12.8 4.7% Currency* 0.7 2.4% Total $ 25.4 $ 26.9 (5.8%) Americas EMEA APAC • Overall: Up 5.9% as reported, includes 5.2% net • Overall: Down 30% as reported, inclu
Slide 5: NPI: Maintain Leadership in Academia, Expand in Industrials of CRO/Pharma
NPI: Maintain Leadership in Academia, Expand in Industrials of CRO/Pharma Research & Discovery, Bridge to Bio-Production Pre-Clinical Toxicology & Safety Pharmacology MOLECULES CELLS ORGANOIDS/ PRECLINICAL CLINICAL ORGANS Mesh MEA VivaMARS™ Behavior SoHo™ Implantable Organoid Platform Monitoring Sys
Slide 6: Financials
6 Financials 6
Slide 7: Q3'23 Performance versus Q3'22
Q3’23 Performance versus Q3’22 $ Million except REVENUE ADJUSTED EBITDA* GROSS MARGIN per share data $25.4 $26.9 $2.2 58% 8.9% $1.0 45% 3.9% Q3’23 Revenue includes $0.1 million and Q3’ 22 includes $1.4 million Q3’22 includes $1.3 million inventory charge related to discontinued in sales of discontin
Slide 8: 2023 Outlook
8 2023 Outlook 8
Slide 9: 2023 Full Year Outlook
2023 Full Year Outlook For FY2023, we expect: ▪ Reported revenue roughly flat compared to prior year, includes approx. 5 percentage points of discontinued products compared to 2022 ▪ Gross Margins to remain strong in the 60% range ▪ Adjusted EBITDA margins in the 13% to 14% range ▪ Improved EBITDA a
Slide 10: Appendix
10 Appendix
Slide 11: Reconciliation to GAAP P&L
11 Reconciliation to GAAP P&L 11 11
Slide 12: Slide 12